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Several studies have identified rare genetic variations responsible for many cases of 
familial breast cancer, but their contribution to total breast cancer incidence is 
relatively small.  More common genetic variations with low penetrance may account 
for a higher proportion of the population risk of breast cancer. 
Methods 
In an effort to identify genes that influence non-familial breast cancer risk, we tested 
over 25,000 single nucleotide polymorphisms (SNPs) that were located within 
approximately 16,000 genes in a genome-wide case-control study in 254 German 
women with breast cancer and 268 age matched women without malignant disease.  
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Initial findings were subsequently verified in two independent case-control 
collections. 
Results 
We identified a marker on chromosome 14q24.3-q31.1 that was weakly associated 
with breast cancer status (OR = 1.5, P = 0.07).  Genotypes for this SNP were also 
significantly associated with indicators of breast cancer severity, including presence 
of lymph node metastases (P = 0.006) and earlier age of onset (P = 0.01).  The 
association with breast cancer status was replicated in two independent samples 
(OR = 1.35, P = 0.05).  High-density association fine mapping showed that the 
association spanned over 80 kb of the first two introns of the zinc-finger gene DPF3 
(also known as CERD4).  One SNP in intron 1 was found to be more strongly 
associated with breast cancer status in all three sample collections (OR = 1.6, P = 
0.003) as well as with increased lymph node metastases (P = 0.01) and tumour size 
(P = 0.01). 
Conclusions 
Polymorphisms in the 5’ region of DPF3 were associated with increased risk of 
breast cancer development, lymph node metastases, age of onset, and tumour size 
in women of European ancestry.  This study suggests that genetic variation in DPF3 
contributes to breast cancer susceptibility and severity in the general population.   
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Introduction 
Breast cancer aetiology is a complex process, involving genes at multiple levels in 
the stages of carcinogenesis, from initial cell cycle dysregulation to metastatic 
potential [1, 2].  Approximately ten percent of breast cancer cases occur within 
families in which the disease segregates in a Mendelian fashion.  BRCA1 and 
BRCA2 are two genes that have been identified to be responsible for a substantial 
proportion of familial breast cancer [3, 4].  Other members in the same DNA repair 
pathway, p53 (Li-Fraumeni syndrome) [5], ATM [6], and PTEN (Cowden disease) [7], 
are also known to contribute to familial cases, yet are more rare.  Such high 
penetrance germ-line mutations are responsible for less than 10% of all breast 
cancer cases.  However, genetic variation is estimated to contribute approximately 
25% to the population risk of breast cancer, likely accounted for by a large number of 
yet undiscovered common, low penetrance alleles [8, 9].  It is possible that these low 
penetrance markers may be useful in the development of practical prognostic and 
diagnostic indicators for the general population.  However, to date there are very few 
genes that have been confirmed to influence the risk of breast cancer in non-familial 
(sporadic) cases. 
 
Many candidate gene studies have been performed to identify the genes that 
contribute to disease risk in sporadic breast cancer cases [10].  Unfortunately, these 
efforts have been largely unsuccessful.  In an effort to identify novel genes involved 
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in breast cancer susceptibility, we have conducted a large-scale, non-familial, case-
control study using more than 25,000 SNPs located within approximately 16,000 
genes.  In this paper we describe variations in intron 1 of DPF3 on chromosome 
14q24.3-q31.1 that are associated with increased risk of breast cancer, lymph node 
involvement, earlier age of diagnosis, and tumour size. 
 
Materials and Methods 
Study Design  
The participants in the large-scale association study (referred to as the discovery 
sample) were recruited among patients attending the Frauenklinik Innenstadt, 
University of Munich, Germany, and comprised 254 breast cancer cases.  At the time 
of assessment, 94 cases (37%) displayed positive lymph node status, and 18 cases 
(7%) had known distant metastases.  Twenty-seven cases (11%) reported having at 
least one first- or second-degree relative with breast cancer.  The median age of 
diagnosis was 56 yr (range = 23-87 yr).  During the same period, 268 controls with a 
median age of 57 yr (range = 17-88 yr) were recruited from patients with benign 
disease being seen at the clinic.  Controls with a reported family history of breast or 
ovarian cancer were excluded from the current study.  Both parents of each study 
participant were reported to be of German descent. 
 
The participants in the German replication sample were recruited from the 
Department of Obstetrics and Gynecology, Technical University of Munich, and 
consisted of 188 cases and 150 controls.  Most breast cancer cases were recruited 
at pre-operative visits, and the female controls were recruited from healthy 
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individuals or patients with non-malignant diagnoses.  Median age of diagnosis for 
cases was 59 yr (range = 22-87 yr) and median age of controls was 50 yr (range = 
19-91 yr).  Two participants reported one parent of non-German, Eastern European 
origin; otherwise both parents were of German descent. 
 
The participants in the Australian replication sample were recruited from the 
Pathology Department of Gold Coast Hospital or by the Genomics Research Center, 
Southport.  The collection included 180 breast cancer cases with a median age of 
diagnosis of 50 yr (range = 24-74 yr).  Controls consisted of 180 healthy volunteers 
without family history of cancer recruited through the Genomics Research Center.  
Controls were individually age matched to cases (±5 yr) with the median age for 
controls at 60 yr (range = 28-94 yr).  
 
All subjects involved in our studies signed a written informed consent and the 
institutional ethics committees of participating institutions approved the experimental 
protocols.  
SNP Markers, Genotyping, and Resequencing 
An assembled set of 25,494 SNP assays as markers for the human genome was 
selected from a larger collection of 125,799 experimentally validated polymorphic 
variations [11].  This set was characterized by SNPs located within gene coding 
regions (within 10 kb of 15,995 LocusLink annotated genes), minor allele frequencies 
greater than 0.02 (95% have frequencies greater than 0.1), and a median inter-
marker spacing of 40 kb.  SNP annotation was based upon the NCBI dbSNP 
database, refSNP build 118 [12].  Genomic annotation was based on NCBI Genome 
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Build 34.  Gene annotation was based upon LocusLink genes for which NCBI was 
providing positions on the Mapview FTP site [13]. 
 
DNA pools were formed by combining equimolar amounts of each sample as 
described elsewhere [14, 15].  For SNP assays carried out on pooled DNA, 25 ng of 
DNA was used.  All PCR and MassEXTEND reactions were conducted using 
standard conditions [15].  Relative allele frequency estimates were derived from 
calculations based on the area under the peak of mass spectrometry measurements 
from four analyte aliquots as described elsewhere [15].  The same procedure was 
used for individual genotyping except 2.5 ng DNA was used and only one mass 
spectrometry measurement was taken.  Primers used for genotyping are presented 
in Table 1.  Sequencing was performed under standard conditions for 
MassCLEAVE[16] using 5 ng of DNA.  For Exon 1, the amplification primers used 
were 5’-AACGGCAGAGCACATGTAGTAA-3’ and 5’-
ATATTGAAACCACGCGGAATA-3’.  For Exon 2, the amplification primers used were 
5’-CTGGGTGTGTTTCAGTCTTCC-3’ and 5’-CTGGTTTCCCAGACAAGCTG-3’. 
Statistical Methods 
Tests of association between disease status and each SNP using pooled DNA were 
carried out in a similar fashion as explained elsewhere [17].  Sources of 
measurement variation included pool formation, PCR/mass extension, and chip 
measurement.  When three or more replicate measurements of an allele frequency 
were available within a model level, the corresponding variance component was 
estimated from the data.  Otherwise, the following historical laboratory averages 
were used: pool formation = 5.0 x 10-5, PCR/mass extension = 1.7 x 10-4, and chip 
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measurement = 1.0 x 10-4.  Tests of association using individual genotypes were 
carried out using a chi-square test of heterogeneity based on allele and genotype 
frequencies.  Selected tests of association involving contingency tables with rare or 
missing cells were carried out using Fisher’s exact test.  The DerSimonian-Laird 
random effects meta-analysis method [18] was used for the analysis of replication 
samples to test for the consistency of association while permitting allele frequencies 
to differ among collections.  All tests of allele frequencies involving only replication 
samples are one-sided, confirming the effect observed in the discovery sample.  P-
values were derived using the log odds of each contrast and their standard errors.  
Multiple approaches were explored in an effort to identify haplotypes demonstrating 
a stronger association with disease status than single sites.  These included 
analyses of 6 SNP haplotypes and subsets thereof using the coalescent theory-
based PHASE v2.0 [19] and the score method that relies on the EM algorithm[20].  
No attempt was made to correct P-values for multiple testing.  Rather, P-values are 
provided to compare the relative strength of association from multiple dependent 
(e.g. SNPs within samples) and independent (e.g. SNPs between samples) sources 
of information.  P-values less than 0.05 are referred to as statistically significant. 
 
Results  
SNP markers associated with breast cancer status were selected for investigation 
using a three-phased approach.  In the first phase, case and control samples were 
pooled, a single PCR reaction and primer extension was performed on each pool; 
case and control, and four measurements of the extension product were collected.  
The relative allele frequencies were compared, and 1,619 SNPs with the most 
statistically significant associations were selected to be tested further in the second 
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phase.  The allele frequencies of these SNPs were then measured again in three 
separate PCR and primer extension reactions for the case and control pools, and 
compared as in the first phase.  The 75 most significant SNPs from the second 
phase were selected for individual genotyping in the samples that comprised the 
case and control pools. 
 
Case-control studies employing tens of thousands of SNPs in a genome-wide 
approach using liberal selection criteria are expected to yield a high proportion of 
false positive associations.  To determine if the observed association was a true 
genetic effect, the 75 SNPs were subsequently genotyped in two additional breast 
cancer case-control collections.  One significant result of the analysis of the 
replication samples was with SNP rs1990440, located on chromosome 14q24.3-
q31.1.  The frequency of the G allele in discovery control subjects was 0.08, similar 
to the NCBI reported average allele frequency [21].  The frequency in case subjects 
was higher (0.12).  Table 2 shows the association with breast cancer for the 
polymorphism genotyped in the discovery and two replication collections.  Even 
though this SNP was only marginally associated in the German discovery sample 
(OR = 1.49, P = 0.069), German replication sample (OR = 1.33, P = 0.29), and 
Australian replication sample (OR = 1.36, P = 0.22), the estimated effects were 
consistent and the analysis of all three samples resulted in a combined significance 
of P = 0.016 (OR = 1.40) and a significance of P = 0.054 (OR = 1.35) within the 
replication samples only.  The marker SNP, rs1990440, resides in intron 1 of DPF3. 
 
To fine map the region of association, we tested an additional 394 SNPs located 
within or near the DPF3 gene using the case and control discovery pools (Figure 1).  
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We observed that the contiguous region of highest significance extended over 65kb, 
spanning the 3’ region of intron 1 with additional evidence for a 10 kb region that 
includes exon 2.  We re-sequenced exons 1 and 2 in 6 breast cancer cases and 5 
controls to determine if any additional SNPs with stronger disease association or 
apparent functional relevance could be discovered.  We identified only one SNP in 
intron 1 that was not publicly annotated (data not shown) and found to have an 
average allele frequency that did not significantly differ between the case and control 
pools.  No previously described SNPs reside in exon 1 or 2, and no novel SNPs 
were discovered by our efforts.  We selected 5 SNPs that differed significantly 
between case and control pools, roughly distanced 20 kb apart, for genotyping in the 
discovery and replication samples and for further analysis (Table 2).  The SNPs most 
strongly associated in the discovery and replication samples, rs4307892, rs4899445 
and rs4378563, were flanking the original marker and were in strong linkage 
disequilibrium (all |D’| > 0.9, r2 > 0.7).  Of the additional SNPs genotyped, rs4899445 
demonstrated the most consistent differences between cases and controls, with a 
slightly larger effect in the discovery sample (OR = 1.56, P = 0.045) and a 
substantially more consistent effect in the German (OR = 1.72, P = 0.094) and 
Australian (OR = 1.47, P = 0.16) replication samples.  The effect of the combined 
replication sample was significant at the 0.05 level (OR = 1.56, P = 0.016) and equal 
to the estimate from all three samples (OR = 1.56, P = 0.003).  Analyses of 
haplotypes consisting of subsets of the 6 genotyped SNPs did not reveal any 
haplotype with stronger association than individual SNPs (data not shown). 
The data from the German breast cancer patients from the discovery collection 
included additional information indicative of family history of breast cancer, age of 
onset, and disease severity.  Further analysis revealed additional associations 
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between the original marker polymorphism in intron 1, rs1990440 C>G, and multiple 
traits indicative of cancer aggressiveness (Table 3), including lower mean age of 
diagnosis of breast cancer (P = 0.01) as well as lymph node involvement (P = 
0.006).  Associations with organ metastases (P = 0.35) and primary tumour size (P = 
0.17) were not statistically significant.  The SNP that was most strongly associated 
with breast cancer risk across all three samples, rs4899445, was also found to be 
significantly associated with lymph node involvement (P = 0.008).  The risk allele 
was also significantly associated with an increase in tumour size (P = 0.007).  
Though not statistically significant, the risk allele carriers tended to be younger at 
age of diagnosis (P = 0.35) and have a higher proportion of breast cancer family 
history (P = 0.13). 
Discussion  
Here, we report variants in DPF3, identified through a large-scale, genome-wide 
association study, that are associated with increased breast cancer risk, lymph node 
involvement, decreased age of onset, and increased tumour size.  Our study 
suggests that individuals that carry one or more G alleles for the initial marker, 
rs199440 C>G in DPF3, have a nominally significant increase in breast cancer risk in 
comparison with the CC homozygotes.  This association was substantiated in two 
independent collections from Germany and Australia.  Fine mapping narrowed the 
region of association down to approximately 80 kb, spanning most of introns one and 
two.  Subsequent genotyping of additional SNPs identified an intron 1 SNP, 
rs4899445, that was more consistently associated with breast cancer status across 
the three samples. 
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DPF3 encodes a zinc finger protein on chromosome 14q24.3-q31.1.  Zinc-fingers 
consist of clusters of cysteines or cysteines and histidines that co-ordinately bind 
zinc ions.  DPF3 is a highly conserved gene homologous to neuro-d4, a member of 
the d4 family of zinc-fingers.  Previous characterization of the DPF3 gene 
demonstrated that while DPF3 is similar to neuro-d4 and ubi-d4/Requiem genes, the 
introns of DPF3 are much larger [22].  This fact, in conjunction with the close 
similarity in the amino acid sequences of the encoded proteins, has led to the 
suggestion that the increase in intron size of DPF3 may result in changes in the 
regulation of DPF3 gene expression.  DPF3 has one C2H2 domain and one PHD 
domain, suggesting a role in the direct binding of DNA and in the assembly of large 
protein complexes.  Functional studies of the d4 gene family have suggested that 
members participate in regulation of myeloid programmed cell death through the 
induction of apoptosis [23].  More recently, DPF3 has been identified by microarray 
analysis as a transcription factor that may play a role in the pathogenesis of incipient 
Alzheimer’s Disease [24].  While limited expression information is available, DPF3 is 
expressed in both normal and cancerous breast tissue and cell lines [25].  
 
While the current study suggests that variants in DPF3 intron 1 are associated with 
increased breast cancer risk, the possible mechanisms by these variants predispose 
to breast cancer are purely speculative.  If the G allele were associated with 
decreased cer-d4 activity (for example by means of transcription down-regulation, 
less active alternatively spliced forms, or reduced levels of properly spliced mRNA 
product) it would suggest that carriers might demonstrate an apoptosis resistant 
phenotype.  Apoptosis is a physiological mechanism of cell death that plays in 
important role in many disease states, including cancer [26].  Imbalance of pro-
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apoptotic and anti-apoptotic proteins, resulting in altered apoptosis, may result in 
tumour development or poor response to adjuvant therapy.  Apoptosis requires de-
novo synthesis of mRNA and protein, and decreased cer-d4 may reduce the 
availability of transcription factors that could be post-translationally activated in 
response to apoptosis-inducing signalling factors. 
 
Regardless of our current lack of understanding of the direct mechanism by which 
DPF3 functions, we provide evidence for an increase in risk of breast cancer 
associated with polymorphisms within the gene.  Additional genetic and experimental 
studies will be required to precisely elucidate the role of DPF3 in breast cancer 
aetiology and progression, and whether genotyping markers within DPF3 could have 
clinical implications for the choice of treatment.  
 
It should be recalled that the marker in DPF3 was one of 75 identified from a large-
scale association study.  The estimated effect of this marker was relatively small and 
would have been discounted had similar effects not been observed in the two 
replication samples.  Even so, the statistical significance observed in the replication 
samples alone for the marker SNP (rs1990440; P = 0.054) or the more significant 
SNP identified nearby (rs4899445; P = 0.016) would not hold up to an experiment-
wide type I error rate of 0.05 after correcting for multiple testing.  Given that that 75 
regions followed up in replication were largely independent on a population level, a 
conservative Bonferroni correction would require P-values to be less than 0.0006 to 
achieve the stated experiment-wide false positive rate.  Under this consideration, we 
concede that these results should be interpreted with caution.  Final validation will 
require analysis in much larger sample collections.  Indeed, if we were to assume 
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that the true effect is as estimated by the replication samples (OR = 1.5) with a 
population allele frequency of 6%, aggregate sample sizes on the order of 1,000 
cases and controls will be necessary to have adequate power to substantiate the 
effect of this region on breast cancer risk.  
Conclusion  
Our study in women of European ancestry identifies associations between 
polymorphisms in DPF3 and breast cancer, lymph node involvement, earlier-onset 
breast cancer, and tumour size.  While three independent samples from the current 
study support the association with breast cancer, additional studies are needed to 
verify the association and to further characterize the gene in order to fully understand 
the role DPF3 may play in the aetiology and progression of breast cancer.  Once 
validated, these and similar, small-effect, emerging and still undiscovered variations 
may play an important role in the assessment of individual breast cancer risks and in 
the decisions surrounding patient care. 
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Fine mapping of breast cancer susceptibility on chromosome 14q24.3-q31.1.  395 SNPs in a 250 kb 
window were compared between pooled cases and controls.  The x-axis corresponds to the 
chromosomal position and the y-axis to the test P-value (shown on the –log10 scale).  The continuous 
dark line represents a goodness–of–fit test for excess of significance (compared to the 0.05 
proportion expected by chance alone) in a 10-kb sliding window assessed at 1-kb increments.  The 
continuous light grey line is the result of a non-linear smoothing function showing a weighted average 
of the P-values across the region.  The shade of each point corresponds to the minor allele frequency 
of the corresponding SNP in the control sample (see legend below graph).  The LocusLink gene 
































5'-TGC TGG GAT TAT GAG CCA CT-3' 
5'-GTG TGT CTC CAG TAA AGG GC-3' 





5'-GCA AAA TGC TAG TAA ATG GTG-3' 
5'-GAA AAA TGG CAA GCC TTC TG-3' 





5'-AAG TCA CTA ACC CCA CAC AC-3' 
5'-CCA GGG TGT GTT CTA ATA CG-3' 





5'-AGG AGA GTC TGC CCA TTT GA-3' 
5'-AGA AAA CTC ACC TCC CTG AC-3' 





5'-GCC GTG TGC ATA TCC TGA TC-3' 
5'-TTA TGG CTT CCT CTC CCT AC-3' 





5'-TTA AAA ATA CAA TGA TGG CC-3' 
5'-TCC CGA CCT CAG GTG ATG TG-3' 
5'-GAT TAC AGG TAT GAG CCA C-3' 
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Table 2 
Distribution of genotype counts and relative allele frequencies of the DPF3 polymorphisms1 in 
both breast cancer and control groups for discovery and replication samples 
Study  Na Genotype count (%) MAFb ORc P-valued 
rs8010957 (Intron 1 G>A)  AA AG GG A  
Case 235 0 (0) 8 (3) 227 (97) 2% German2 Control 256 0 (0) 23 (9) 233 (91) 5% 0.34 0.006 
Case 182 0 (0) 9 (5) 173 (95) 2% German3 Control 134 0 (0) 7 (5) 127 (95) 3% 0.94 0.912 
Case 163 0 (0) 5 (3) 158 (97) 2% Australian Control 164 0 (0) 8 (5) 156 (95) 2% 0.62 0.407 
                                                        Replication only 0.79 0.270 
                                                           Total (all of centres) 0.55 0.058 
 
rs4307892 (Intron 1 G>A)  AA AG GG A   
Case 238 2 (1) 59 (25) 177 (74) 13% German2 Control 252 1 (0) 44 (17) 213 (83) 9% 1.56 0.030 
Case 185 1 (1) 40 (22) 144 (78) 11% German3 Control 141 2 (1) 19 (13) 120 (85) 8% 1.44 0.177 
Case 173 0 (0) 33 (19) 140 (81) 10% Australian Control 171 1 (1) 25 (15) 145 (85) 8% 1.23 0.445 
                                                          Replication only 1.33 0.068 
                                                           Total (all of centres) 1.43 0.010 
 
rs19904404 (Intron 1 C>G)  GG GC CC G   
Case 206 2 (1) 46 (22) 158 (77) 12% German2 Control 253 2 (1) 39 (15) 212 (84) 8% 1.49 0.069 
Case 191 1 (1) 39 (20) 151 (79) 11% German3 Control 145 1 (1) 22 (15) 122 (84) 8% 1.33 0.286 
Case 180 1 (2) 34 (19) 144 (80) 11% Australian Control 171 1 (1) 25 (15) 145 (85) 8% 1.36 0.224 
                                                          Replication only 1.35 0.054 
                                                           Total (all of centres) 1.40 0.016 
 
rs4899445 (Intron 1 A>G)  GG GA AA G  
Case 240 2 (1) 48 (20) 190 (79) 11% German2 Control 257 1 (0) 35 (14) 221 (86) 7% 1.56 0.045 
Case 185 2 (1) 28 (15) 155 (84) 9% German3 Control 143 0 (0) 15 (10) 128 (90) 5% 1.72 0.094 
Case 176 1 (1) 33 (19) 142 (81) 10% Australian Control 172 1 (1) 22 (13) 149 (87) 7% 1.47 0.160 
                                                          Replication only 1.56 0.016 
                                                           Total (all of centres) 1.56 0.003 
 
rs4378563 (Intron 1 C>T)  TT CT CC T   
Case 235 2 (1) 58 (25) 175 (74) 13% German2 Control 252 2 (1) 34 (13) 216 (86) 8% 1.86 0.004 
Case 175 1 (1) 30 (17) 144 (82) 9% German3 Control 131 1 (1) 19 (15) 111 (85) 8% 1.15 0.624 
Case 162 1 (1) 30 (19) 131 (81) 10% Australian Control 167 1 (1) 26 (16) 140 (84) 8% 1.20 0.506 
                                                          Replication only 1.18 0.210 
                                                           Total (all of centres) 1.44 0.027 
 
rs12232220 (Intron 2 G>A)  AA AG GG A   
Case 237 0 (0) 16 (7) 221 (93) 3% German2 Control 253 1 (0) 28 (11) 224 (89) 6% 0.55 0.059 
Case 186 0 (0) 25 (13) 161 (87) 7% German3 Control 144 0 (0) 9 (6) 135 (94) 3% 2.23 0.038 
Case 166 0 (0) 16 (10) 150 (90) 5% Australian Control 169 0 (0) 13 (8) 156 (92) 4% 1.27 0.536 
                                                          Replication only 1.66 0.960 
                                                           Total (all of centres) 1.13 0.770 
 
aNumber of subjects with genotypes. bMinor relative allele frequency. cOdds ratio for the allele that increases in the case group. 
dP-value for tests comparing genotype frequencies between cases and controls. 1Presented in order respective to position in 
DPF3. 2German discovery sample. 3German replication sample. 4Marker SNP identified in large-scale association study. 
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 Table 3  
Association of the DPF3 polymorphisms with traits of interest in discovery breast cancer 
cases 
Trait Genotype Estimates P-value 
rs4307892 G>A N 
AA  
N = 2 
AG  
N = 59 
GG 
N = 177   
Age of Diagnosis (Years) 235 49.6 54.5 59.4 45.1 54.6 60.3 51.2 56.9 63.5 0.0981 
Years since diagnosis 233 4.6 8.3 12.1 0.6 2.8 5.7 0.6 2.2 5.9 0.7931 
Familial Breast Cancer History 254 1 (50) 6 (10) 17 (10) 0.2552 
Primary tumour3 236 0 (0) 22 (37) 47 (28) 0.3182 
Lymph node metastases (Yes)  254 2 (100) 23 (39) 46 (26) 0.0142 
Organ metastases (Yes)  254 0 (0) 6 (10) 10 (6) 0.3392 
rs1990440 C>G N 
GG 
N = 2 
GC 
N = 46 
CC 
N = 158  
Age of Diagnosis (Years) 235 49.6 54.5 59.4 45.0 51.7 60.1 51.9 57.4 65.0 0.0121 
Years since diagnosis 233 4.6 8.3 12.1 0.4 3.0 6.8 0.6 2.2 5.4 0.7621 
Familial Breast Cancer History 254 1 (50) 6 (13) 15 (9) 0.1652 
Primary tumour3 236 0 (0) 20 (43) 44 (30) 0.1692 
Lymph node metastases (Yes) 254 2 (100) 19 (41) 39 (25) 0.0062 
Organ metastases (Yes) 254 0 (0) 6 (13) 11 (7) 0.3472 
rs4899445 A>G N 
GG 
N = 2 
GA 
N = 48 
AA 
N = 190  
Age of Diagnosis (Years) 235 49.6 54.5 59.4 46.4 53.8 60.6 50.6 56.5 63.3 0.3501 
Years since diagnosis 233 4.6 8.3 12.1 0.7 2.8 5.7 0.6 2.3 5.9 0.7431 
Familial Breast Cancer History 254 1 (50) 6 (12) 17 (9) 0.1322 
Primary tumour3 236 0 (0) 23 (48) 47 (26) 0.0072 
Lymph node metastases (Yes) 254 2 (100) 20 (42) 50 (26) 0.0082 
Organ metastases (Yes) 254 0 (0) 5 (10) 11 (6) 0.4152 
rs4378563 C>T N 
TT 
N = 2 
TC 
N = 58 
CC 
N = 175  
Age of Diagnosis (Years) 235 49.6 54.5 59.4 46.0 53.8 60.6 51.0 56.9 63.4 0.2121 
Years since diagnosis 233 4.6 8.3 12.1 0.4 2.5 6.0 0.7 2.3 6.0 0.7231 
Familial Breast Cancer History 254 1 (50) 5 (9) 16 (9) 0.2742 
Primary tumour3 236 0 (0) 26 (46) 43 (26) 0.0112 
Lymph node metastases (Yes)  254 2 (100) 23 (40) 46 (26) 0.0132 
Organ metastases (Yes)  254 0 (0) 6 (10) 10 (6) 0.3382 
 
abc represent the lower quartile a, the median b, and the upper quartile c for continuous variables. 1Kruskal-Wallis test. 2Fisher’s 
exact test. 3 T > 2 cm 
 
 
 
 
